Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sourcebio International Plc
  6. News
  7. Summary
    SBI   GB00BKSB1674

SOURCEBIO INTERNATIONAL PLC

(SBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sourcebio International plc Announces National Framework Contract

05/20/2021 | 02:00am EST

SourceBio International plc announced that it has been successful with its tender for the Lot 4 Framework Agreement under Public Health England's ("PHE") National Microbiology Framework to provide its Clinical Laboratory Diagnostic Testing Services. PHE's National Microbiology Framework is appointing suppliers to framework agreements in four lots. Lot 4 covers Clinical Laboratory Diagnostic Testing Services, utilising new and existing techniques to ensure that there are consistent and affordable provision of high quality, safe and compliant testing services which should be delivered efficiently and effectively to support wider clinical services. The term of the Framework Agreement for Lot 4 is for an initial two years with the option to extend by up to a further two years. Under the National Microbiology Framework, participating public health authorities across the United Kingdom can use any of the 50 qualifying companies of Lot 4 to call-off contracts to procure goods and testing services. One of which is SourceBio, however this agreement is not exclusive to SourceBio and does not guarantee orders.


ę S&P Capital IQ 2021
All news about SOURCEBIO INTERNATIONAL PLC
09/28Sourcebio International plc Reports Consolidated Earnings Results for the Six Months En..
CI
09/20SOURCEBIO INTERNATIONAL : Signs Supply Agreements For COVID-19 Lateral Flow Tests In UK
MT
07/27Sourcebio International Plc Reports Earnings Results for the First Half Ended 30 June 2..
CI
07/27Sourcebio International Plc Provides Revenue Guidance for the Second Half of Fiscal Yea..
CI
05/20Sourcebio International plc Announces National Framework Contract
CI
04/13Sourcebio International Plc Reports Consolidated Earnings Results for the Year Ended De..
CI
03/08SOURCEBIO INTERNATIONAL : to Provide COVID-19 Testing Services to English Rugby Teams
MT
03/08Sourcebio International plc Enters into an Agreement with the Rugby Football Union and ..
CI
03/03Sourcebio International Plc Announces Laboratory Operations in San Diego, California, t..
CI
02/19SOURCEBIO INTERNATIONAL : Up 7% After Securing COVID-19 Mobile Testing Contract
MT
More news
Analyst Recommendations on SOURCEBIO INTERNATIONAL PLC
More recommendations
Financials
Sales 2021 86,5 M 115 M 115 M
Net income 2021 - - -
Net cash 2021 21,5 M 28,5 M 28,5 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 106 M 140 M 140 M
EV / Sales 2021 0,97x
EV / Sales 2022 1,37x
Nbr of Employees 194
Free-Float 91,3%
Chart SOURCEBIO INTERNATIONAL PLC
Duration : Period :
Sourcebio International Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOURCEBIO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 142,50 GBX
Average target price 190,00 GBX
Spread / Average Target 33,3%
Managers and Directors
Anthony James Ratcliffe CFO, Secretary & Executive Director
Jay Charles LeCoque Executive Chairman
Russell Steven Wheatcroft Chief Operating Officer
Ian James Carruthers Senior Independent Non-Executive Director
Simon John Constantine Independent Non-Executive Director